We highlight concerns regarding the approval of relugolix for patients with prostate cancer. These include the unsuitable comparator arm and primary endpoint in the HERO trial, as well as potential selection bias and the poor representativeness of the trial population. Dosing adherence to a daily ta …
Manyak, a world-renown expert in backcountry medicine, former NESA vice president and a Distinguished Eagle Scout, was 73.
Residents Bowl emcee Gary Faerber, MD, looks back on more than a decade of fun and challenges.
At the American Society of Clinical Oncology Genitourinary Cancer Symposium, Judd W. Moul, MD, a urologist at Duke Cancer Institute, offered his insights on …
Purpose:Transrectal prostate biopsy has come under scrutiny due to potential for postbiopsy infections and transperineal prostate biopsy is being offered as the safer alternative. However,…
Available data support the improved detection performance and selectivity of NGI modalities versus conventional imaging techniques; however, limited clinical evidence exists demonstrating the application of…
This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients…
Abstract/Video/T. Leon Howard Case Submissions Welcome Guest Submission Dates System is Open Open: June 21, 2023 12:00 AM (Central Time U.S. & Canada) Closes:…
Cartesian Therapeutics and National Institute of Neurological Disorders and Stroke of the National Institutes of Health.
